Evidence map›Paper›PMID 31087225›Full record

ArticleClinical rheumatology2020

Risk of bleeding events among patients with systemic sclerosis and the general population in the UK: a large population-based cohort study.

Alexander Michel, Antonio González-Pérez, María E Sáez, Luis A García Rodríguez

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. An unusual complication of kidney biopsy: a case report.Journal of medical case reports · 2024
    Article
  4. Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Alexander MichelEpidemiology, Division Pharmaceuticals, Bayer Consumer Care AG, Basel, Switzerland. alexander.michel@bayer.com.
Antonio González-PérezSpanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
María E SáezSpanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
Luis A García RodríguezSpanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
Centro Español de Investigación Farmacoepidemiológica · ESBayer (Switzerland) · CHInstituto Ramón y Cajal de Investigación Sanitaria · ES

Funding

Bayer NA
6 · The paper itself

Abstract

INTRODUCTION/

objectivesTo compare the risk of different bleeding outcomes between patients with systemic sclerosis (SSc) and the general population free of SSc.

methodsUsing UK electronic primary care data (2000-2012), 1314 patients with SSc and a matched SSc-free comparison cohort (n = 19,992) were followed until December 2013 to identify bleeding, confirmed following manual review of patient records including free text comments. Incidence rates were calculated and Cox regression used to estimate adjusted hazard ratios (HRs; SSc cohort vs. matched general population cohort) adjusted for confounders.

resultsOne hundred and twenty-seven bleeding events occurred in the SSc cohort and 1762 in the general population cohort; incidence rates per 1000 person-years for the SSc cohort and general population cohort were 0.5 versus 0.3 for hemorrhagic stroke, 4.1 versus 3.3 for gastrointestinal bleeding, 2.5 versus 1.7 for pulmonary hemorrhage, 8.4 versus 7.5 for urogenital bleeding, and 15.5 versus 12.9 for any of the aforementioned bleedings. Adjusted HRs (95% confidence intervals) were 1.21 (1.00-1.46) for any bleeding, 1.51 (0.54-4.21) for hemorrhagic stroke, 1.50 (0.96-2.35) for pulmonary hemorrhage, 1.08 (0.75-1.54) for gastrointestinal bleeds, and 1.28 (1.00-1.64) for urogenital bleeds. HRs were more often higher in SSc patients with organ involvement than without organ involvement and in those with diffuse cutaneous SSc.

conclusionOur results are consistent with a moderately increased risk of bleeding in SSc patients. Further evidence from large SSc patient cohorts is needed to confirm this finding.Key Points• The risk of experiencing a major bleed may be higher among patients with SSc than the general population.• Further large and well-designed studies are needed to corroborate our findings.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCohort StudiesDatabases, FactualFemaleHemorrhageHumansInfantInfant, NewbornMaleMiddle AgedProportional Hazards ModelsCohort studiesHemorrhageSclerodermaSystemicUnited Kingdom

Identifiers

PMID31087225
OpenAlexW2945302305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.